US6936694B1
(en)
|
1982-05-06 |
2005-08-30 |
Intermune, Inc. |
Manufacture and expression of large structural genes
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
CA2006596C
(en)
*
|
1988-12-22 |
2000-09-05 |
Rika Ishikawa |
Chemically-modified g-csf
|
US6372206B1
(en)
*
|
1989-03-02 |
2002-04-16 |
University Of Florida |
Orally-administered interferon-TAU compositions and methods
|
US5906816A
(en)
*
|
1995-03-16 |
1999-05-25 |
University Of Florida |
Method for treatment of autoimmune diseases
|
US5372808A
(en)
†
|
1990-10-17 |
1994-12-13 |
Amgen Inc. |
Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
|
US5676942A
(en)
*
|
1992-02-10 |
1997-10-14 |
Interferon Sciences, Inc. |
Composition containing human alpha interferon species proteins and method for use thereof
|
DE69324671D1
(de)
*
|
1992-02-10 |
1999-06-02 |
Interferon Sciences Inc |
Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
|
US6001589A
(en)
*
|
1993-06-11 |
1999-12-14 |
Pbl Biomedical Laboratories, Inc. |
Method of identifying proteins modified by disease states related thereto
|
EP0751955A4
(en)
|
1993-06-11 |
1998-10-07 |
Pestka Biomedical Lab Inc |
SUPER PROTEINS COMPRISING INTERFERONS AND INTERLEUKINS
|
WO1995015177A2
(en)
*
|
1993-12-02 |
1995-06-08 |
President And Fellows Of Harvard College |
Improved efficacy of alpha-helical cytokines
|
EP1090645B1
(en)
*
|
1994-02-08 |
2005-12-07 |
Amgen Inc., |
Oral delivery of chemically modified proteins
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
IL116730A0
(en)
*
|
1995-01-13 |
1996-05-14 |
Amgen Inc |
Chemically modified interferon
|
WO1997007820A1
(fr)
*
|
1995-08-30 |
1997-03-06 |
Toray Industries, Inc. |
Remede destine aux maladies cardiaques
|
US5908621A
(en)
*
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
CA2329474C
(en)
|
1995-11-02 |
2002-02-26 |
Schering Corporation |
Continuous low-dose cytokine infusion therapy
|
US5739313A
(en)
*
|
1995-11-13 |
1998-04-14 |
Regents Of The University Of Minnesota |
Radionuclide labeling of vitamin B12 and coenzymes thereof
|
US20030026779A1
(en)
*
|
1999-10-15 |
2003-02-06 |
Liming Yu |
Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
|
US5980884A
(en)
*
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
NZ332689A
(en)
*
|
1996-05-09 |
2000-07-28 |
Pharma Pacific Pty Ltd |
Using interferon to treat autoimmune, mycobacterial or neurodegenerative disease
|
US5831062A
(en)
*
|
1996-05-09 |
1998-11-03 |
Amgen Inc. |
Use of the human interferon consensus gene for gene therapy
|
AUPN976596A0
(en)
*
|
1996-05-09 |
1996-05-30 |
Pharma Pacific Pty Ltd |
Stimulation of host defence mechanisms
|
US20030190307A1
(en)
*
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
US6013253A
(en)
*
|
1997-08-15 |
2000-01-11 |
Amgen, Inc. |
Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
|
US6017876A
(en)
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
AU6390299A
(en)
*
|
1998-09-29 |
2000-04-17 |
W. Robert Fleischmann |
Methods of treating diseased cells
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
US6451346B1
(en)
*
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
RU2140285C1
(ru)
|
1999-01-25 |
1999-10-27 |
Гапонюк Петр Яковлевич |
Противовирусное средство - капли в нос "гриппферон"
|
ES2204509T3
(es)
*
|
1999-01-29 |
2004-05-01 |
F. Hoffmann-La Roche Ag |
Conjugados de gcsf.
|
US6806363B1
(en)
|
1999-04-16 |
2004-10-19 |
Mayo Foundation For Medical Education & Research |
Cobalamin conjugates useful as antitumor agents
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
US7591995B2
(en)
*
|
1999-10-15 |
2009-09-22 |
Mayo Foundation For Medical Education And Research |
Cobalamin conjugates useful as imaging and therapeutic agents
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
WO2001092282A2
(en)
|
2000-05-26 |
2001-12-06 |
Idenix (Cayman) Limited |
Methods and compositions for treating flaviviruses and pestiviruses
|
US7105154B2
(en)
*
|
2000-07-19 |
2006-09-12 |
Pepgen Corporation |
Method of treatment using interferon-tau
|
CA2427146A1
(en)
|
2000-10-25 |
2002-07-18 |
Mayo Foundation For Medical Education And Research |
Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
|
US6878364B2
(en)
*
|
2000-12-01 |
2005-04-12 |
Cornell Research Foundation, Inc. |
Animal model for flaviviridae infection
|
US20060035327A1
(en)
*
|
2001-02-28 |
2006-02-16 |
Guangwen Wei |
Recombinant super-compound interferon and uses thereof
|
CN1245215C
(zh)
*
|
2001-02-28 |
2006-03-15 |
四川省生物工程研究中心 |
重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
|
US20050079579A1
(en)
*
|
2001-02-28 |
2005-04-14 |
Guangwen Wei |
Uses of spatial configuration to modulate protein function
|
US8551469B2
(en)
*
|
2001-02-28 |
2013-10-08 |
Superlab Far East Limited |
Treatment of tumors and viral diseases with recombinant interferon alpha
|
US20030104996A1
(en)
*
|
2001-08-30 |
2003-06-05 |
Tiansheng Li |
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
|
PL369129A1
(en)
*
|
2001-09-28 |
2005-04-18 |
Intermune, Inc. |
Method for treating hepatitis c virus infection in treatment failure patients
|
US7138376B2
(en)
*
|
2001-09-28 |
2006-11-21 |
Idenix Pharmaceuticals, Inc. |
Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
|
JP2005508332A
(ja)
*
|
2001-09-28 |
2005-03-31 |
メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ |
薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
|
EP1435997A4
(en)
*
|
2001-09-28 |
2006-03-01 |
Intermune Inc |
TECHNIQUE FOR TREATING HEPATITIS C VIRUS INFECTION FOR PATIENTS WHOSE TREATMENT FAILED
|
WO2003030923A1
(en)
*
|
2001-10-05 |
2003-04-17 |
Intermune, Inc. |
Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
|
JP2005517648A
(ja)
*
|
2001-12-07 |
2005-06-16 |
インターミューン インコーポレイテッド |
肝炎ウイルス感染症を治療するための組成物および方法
|
KR20040083421A
(ko)
*
|
2002-01-16 |
2004-10-01 |
펩젠 코포레이션 |
인터페론-타우의 경구 투여
|
US20040063912A1
(en)
*
|
2002-03-15 |
2004-04-01 |
The Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
CA2489552A1
(en)
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
PL374831A1
(en)
|
2002-06-28 |
2005-10-31 |
Idenix (Cayman) Limited |
Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
CN101172993A
(zh)
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
|
GB0215293D0
(en)
*
|
2002-07-03 |
2002-08-14 |
Rega Foundation |
Viral inhibitors
|
AU2003298658A1
(en)
|
2002-11-15 |
2004-06-15 |
Idenix (Cayman) Limited |
2'-branched nucleosides and flaviviridae mutation
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
KR20050109918A
(ko)
|
2002-12-12 |
2005-11-22 |
이데닉스 (케이만) 리미티드 |
2'-분지형 뉴클레오시드의 제조 방법
|
US20070077225A1
(en)
*
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
EP1599171A2
(en)
*
|
2003-02-28 |
2005-11-30 |
Intermune, Inc. |
Combination therapy for treating alphavirus infection and liver fibrosis
|
EP1633766B1
(en)
|
2003-05-30 |
2019-03-06 |
Gilead Pharmasset LLC |
Modified fluorinated nucleoside analogues
|
CN1852915A
(zh)
*
|
2003-07-25 |
2006-10-25 |
艾登尼科斯(开曼)有限公司 |
治疗包括丙型肝炎的黄病毒科病毒所致疾病的嘌呤核苷类似物
|
KR20060133949A
(ko)
|
2003-08-28 |
2006-12-27 |
휴이양테크 (유에스에이), 인크. |
단백질 기능을 조절하기 위한 공간 배열의 용도
|
US7585647B2
(en)
*
|
2003-08-28 |
2009-09-08 |
Guangwen Wei |
Nucleic acid encoding recombinant interferon
|
US20050208019A1
(en)
*
|
2003-08-28 |
2005-09-22 |
Guangwen Wei |
Uses of interferons with altered spatial structure
|
NZ546347A
(en)
|
2003-10-14 |
2009-11-27 |
Intermune Inc |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
|
WO2005063744A2
(en)
*
|
2003-12-22 |
2005-07-14 |
K.U. Leuven Research & Development |
IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
|
AU2004313245B2
(en)
|
2003-12-30 |
2011-04-14 |
Durect Corporation |
Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
|
WO2005107742A1
(en)
|
2004-05-05 |
2005-11-17 |
Yale University |
Novel antiviral helioxanthin analogs
|
WO2005113592A2
(en)
|
2004-05-19 |
2005-12-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
PL3109244T3
(pl)
|
2004-09-14 |
2019-09-30 |
Gilead Pharmasset Llc |
Wytwarzanie 2'fluoro-2'-alkilo-podstawionych lub innych ewentualnie podstawionych rybofuranozylopirymidyn i puryn oraz ich pochodnych
|
EP1679065A1
(en)
*
|
2005-01-07 |
2006-07-12 |
OctoPlus Sciences B.V. |
Controlled release compositions for interferon based on PEGT/PBT block copolymers
|
EP2749290A3
(en)
|
2005-03-09 |
2015-02-18 |
Guangwen Wei |
Uses of recombinant super-compound interferons
|
JP4516863B2
(ja)
*
|
2005-03-11 |
2010-08-04 |
株式会社ケンウッド |
音声合成装置、音声合成方法及びプログラム
|
BRPI0609809A2
(pt)
|
2005-05-18 |
2011-10-11 |
Maxygen Inc |
polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
|
EP2103623A3
(en)
|
2005-07-25 |
2009-12-16 |
Intermune, Inc. |
Novel macrocyclic inhibitors of Hepatitis C virus replication
|
GEP20104956B
(en)
|
2005-10-11 |
2010-04-12 |
Array Biopharma Inc |
Compounds for inhibiting hepatitis c viral replication and use thereof
|
WO2007075876A2
(en)
|
2005-12-23 |
2007-07-05 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
CA2648077A1
(en)
*
|
2006-03-31 |
2007-11-08 |
Schering Corporation |
Parenteral low dose type 1 interferons for bladder cancer
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CN101525381B
(zh)
*
|
2008-03-04 |
2012-04-18 |
北京百川飞虹生物科技有限公司 |
一种重组复合干扰素及其表达载体的构建和表达
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
JP5793084B2
(ja)
|
2008-12-23 |
2015-10-14 |
ギリアド ファーマセット エルエルシー |
プリンヌクレオシドの合成
|
TW201026715A
(en)
|
2008-12-23 |
2010-07-16 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
MX2011006890A
(es)
*
|
2008-12-23 |
2011-07-20 |
Pharmasset Inc |
Analogos de nucleosidos.
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
EP2440251A4
(en)
*
|
2009-06-09 |
2013-01-16 |
Defyrus Inc |
INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
|
EP2459211A1
(en)
|
2009-07-31 |
2012-06-06 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon- to hepatitis c infected patients
|
CN102101886A
(zh)
*
|
2009-12-18 |
2011-06-22 |
四川辉阳生命工程股份有限公司 |
构象改变的重组干扰素晶体、其三维结构及应用
|
PT2552930E
(pt)
|
2010-03-31 |
2015-11-17 |
Gilead Pharmasset Llc |
2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin- 1-(2h)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2- il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropilo cristalino
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
CN102711871A
(zh)
|
2010-06-16 |
2012-10-03 |
麦德托尼克公司 |
用于稳定药物递送装置中的药物的阻尼系统
|
EP3241558B1
(en)
|
2010-09-28 |
2021-03-03 |
Aegerion Pharmaceuticals, Inc. |
Highly soluble leptins
|
CA2818853A1
(en)
|
2010-11-30 |
2012-06-07 |
Gilead Pharmasset Llc |
2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
|
BRPI1107312B1
(pt)
*
|
2011-11-25 |
2021-09-08 |
Universidade Federal De Santa Catarina |
Composto de acil-hidrazona
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
TWI718086B
(zh)
*
|
2013-01-07 |
2021-02-11 |
英屬維爾京群島商遠東超級實驗室有限公司 |
通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
|
MX2016002185A
(es)
|
2013-08-27 |
2016-06-06 |
Gilead Pharmasset Llc |
Formulacion combinada de dos compuestos antivirales.
|